StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Trading Down 25.5 %

Shares of BLPH stock opened at $0.01 on Friday. The company’s fifty day moving average price is $0.03 and its 200-day moving average price is $0.04. The stock has a market cap of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 12 month low of $0.01 and a 12 month high of $0.02.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.